摘要
目的：比较紫杉醇脂质体＋奥沙利铂＋替吉奥化疗方案及多西他赛＋顺铂＋氟尿嘧啶化疗方案（ DCF）两种化疗方案治疗晚期胃癌的疗效和安全性。方法2012年1月至2013年12月我院住院治疗的45例胃癌晚期患者均经病理组织学和细胞学检查确诊，分为研究组与对照组，分别给与紫杉醇脂质体＋奥沙利铂＋替吉奥化疗方案及多西他赛＋顺铂＋氟尿嘧啶化疗方案（ DCF ），比较两组患者疗效及毒副反应。结果研究组反应率为40．9%，控制率为86．3%；对照组反应率为38．1%，控制率为90．4%，两组相比差异均无统计学意义（ P〉0．05）。两组患者均完成随访，随访6-23个月。研究组中位疾病无进展时间为29周，对照组中位疾病无进展时间为23周，经Log-rank法比较两组差异有统计学意义（P〈0．05）。两组患者比较，研究组消化道反应Ⅲ-Ⅳ级所占百分比为13．6%（3/22），对照组为42．8%（9/21），两组比较差异有统计学意义（P 〈0．05）；研究组白细胞减少Ⅲ-Ⅳ级所占百分比为9．0%（2/22），对照组为38．1%（8/21），两组比较差异有统计学意义（P〈0．05）；研究组贫血Ⅲ-Ⅳ级所占百分比为13．6%（3/22），对照组为47．6%（10/21），两组比较差异有统计学意义（P〈0．05）。结论紫杉醇脂质体＋奥沙利铂＋替吉奥是治疗晚期胃癌疗效较好，毒副反应较轻，值得进一步研究。
Objective To compare the efficacy and safety of Paclitaxel liposome ＋ oxaliplatin ＋ S-1 chemotherapy regimen and Docetaxel ＋ cisplatin ＋ fluorouracil chemotherapy regimen（DCF）in advanced gastric cancer. Methods 45 patients with confirmed diagnosis of advanced gastric cancer by histopathological and cytological examination from January 2012-December 2013 were divided into research group and control group. The research group was given the Paclitaxel liposome ＋ oxaliplatin ＋S-1 chemotherapy,and the control group had the DCF. The efficacy and toxicside effects were compared. Results The reaction rate of study group was 40. 9%, control rate was 86. 3%, control group response rate was 38. 1%, control rate was 90. 4%, and there was no significant difference between the two groups（P〉0. 05）. Both the two groups were followed up for 6-23 months. The progression free time for the study group was 29 weeks,and the control group was 23 weeks. The difference between the two groups was statistically significant（P〈0. 05）by Logrank method. The percentage of Ⅲ-Ⅳ degree of digestive tract reaction in the study group was 13. 6%（3/22）,the control group was 42. 8%（9/21）,and the difference was statistically significant（P〈0. 05）;the percentage of Ⅲ-Ⅳ white blood cells decrease in the study group was 9%（2/22）,the control group was 38. 1%（8/21）,and there was significant difference between the two groups（P〈0. 05）;the percentage of anemia in the study group was 13. 6%（3/22）,the control group was 47. 6%（10/21）,the difference between the two groups was statistically significant（P〈0. 05）. Conclusion Paclitaxel liposome ＋ oxaliplatin ＋ S-1 has better curative effect and less side effects in the treatment of advanced gastric cancer, and it is worthy of further study.
出处
《四川医学》
CAS
2016年第10期1171-1174,共4页
Sichuan Medical Journal
